Lenvatinib Mesylate

• Lenvatinib Mesylate is a multi-kinase inhibitor used in cancer treatment.
• It targets receptors crucial for tumor growth and angiogenesis, such as VEGFR1-3, FGFR1-4, PDGFRα, KIT, and RET.
• The medication is approved for several cancers, including differentiated thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma.
• Dosage varies significantly based on the specific cancer being treated and individual patient factors.
• Common side effects include hypertension, fatigue, diarrhea, and decreased appetite, requiring careful monitoring.

What is Lenvatinib Mesylate and How It Works?

Lenvatinib Mesylate is an oral multi-kinase inhibitor that targets several receptor tyrosine kinases (RTKs) involved in tumor growth, angiogenesis (the formation of new blood vessels), and other processes that support cancer progression. This medication is a crucial tool in modern oncology, designed to specifically interfere with the signaling pathways that cancer cells exploit to grow and spread.

Lenvatinib Mesylate works by inhibiting the activity of various RTKs, including vascular endothelial growth factor receptor (VEGFR) 1, 2, and 3; fibroblast growth factor receptor (FGFR) 1, 2, 3, and 4; platelet-derived growth factor receptor alpha (PDGFRα); KIT; and RET. By blocking these receptors, Lenvatinib Mesylate disrupts the signals that promote blood vessel formation within tumors, thereby starving them of nutrients and oxygen. It also directly inhibits cancer cell proliferation and survival. This multi-targeted approach helps to control tumor growth and improve patient outcomes across several cancer types.

Lenvatinib Mesylate: Uses and Dosage

Lenvatinib Mesylate is used for treating several types of cancer, either alone or in combination with other therapies. Its approved indications include differentiated thyroid cancer (DTC) that is refractory to radioactive iodine, unresectable hepatocellular carcinoma (HCC), advanced renal cell carcinoma (RCC) in combination with everolimus or pembrolizumab, and advanced endometrial carcinoma in combination with pembrolizumab. The specific use depends on the cancer type, stage, and previous treatments, as determined by an oncologist.

Lenvatinib Mesylate dosage information is highly individualized and depends on the specific cancer being treated, the patient’s body surface area, and their overall health, including liver and kidney function. For example, in differentiated thyroid cancer, a common starting dose is 24 mg orally once daily. For hepatocellular carcinoma, the dose is typically 8 mg or 12 mg orally once daily, depending on body weight. In renal cell carcinoma, when used in combination with everolimus, the Lenvatinib Mesylate dose is usually 18 mg orally once daily. Doses may be adjusted by the treating physician based on the patient’s tolerance and response to treatment. It is critical for patients to follow their doctor’s instructions precisely regarding dosage and administration.

Lenvatinib Mesylate Side Effects

Like all potent medications, Lenvatinib Mesylate can cause a range of side effects, which vary in severity and frequency among individuals. Awareness and management of these effects are crucial for maintaining treatment adherence and patient quality of life. Common Lenvatinib Mesylate side effects often include:

• Hypertension (high blood pressure)
• Fatigue and asthenia (lack of energy)
• Diarrhea
• Decreased appetite and weight loss
• Nausea and vomiting
• Proteinuria (protein in the urine)
• Palmar-plantar erythrodysesthesia syndrome (hand-foot syndrome)
• Headache
• Dysphonia (hoarseness)

More serious, though less common, side effects can include cardiac dysfunction, arterial thromboembolic events, hemorrhage, gastrointestinal perforation or fistula formation, hepatotoxicity, and renal failure. Patients are closely monitored for these potential complications throughout their treatment. Any new or worsening symptoms should be reported to a healthcare provider immediately to ensure timely management and dose adjustments if necessary. Regular blood pressure checks and laboratory tests are standard practice during Lenvatinib Mesylate therapy.